Development of An Inflammatory Response-Related Gene Signature To Predict Prognosis and Immunotherapy Response For Patients With Glioma
Abstract Inflammatory response plays a crucial role in the development and progression of gliomas. However, the prognostic value of inflammatory response-related genes has never been comprehensively investigated for glioma. In this study, we identified 39 differentially expressed genes (DEGs) between glioma and normal brain tissue samples, of which 31 inflammatory response-related genes are related to the prognosis of glioma., The 8 optimal inflammatory response-related genes were selected to construct prognostic inflammatory response-related gene signature (IRGS) through the least absolute shrinkage and selection operator (LASSO) penalized Cox regression analysis. The effectiveness of the IRGS was verified in the training (TCGA) and validation (CGGA-693 CGGA-325 and Rembrandt) cohorts. The Kaplan-Meier curve revealed a significant difference in the OS between the high- and low-risk groups. The receiver operating characteristic curve (ROC) shows the powerful predictive ability of IRGS. Meanwhile, a nomogram with better accuracy was established to predict overall survival (OS) based on the independent prognostic factors (IRGS, age, WHO grade, and 1p19q codeletion). In addition, patients in the high-risk group had higher immune, stroma, and ESTIMATE scores, lower tumor purity, higher infiltration of immunosuppressive cells, higher expression of immune checkpoints, higher expression of TIDE and Exclusion, and lower expression of MSI Expe Sig. Thus, the patients in the low-risk group had significantly higher respond rate of immune checkpoint inhibitors (ICIs). A novel prognostic signature incorporated 8 inflammatory response-related genes was associated with the prognosis, immune landscape and the immunotherapy response in patients with gliomas. Thus, the signature can be suitable for future clinical application to predict the prognosis of patients with glioma.